AbbVie announced that the FDA has granted Orphan Drug designation to Humira (adalimumab) for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis.

Humira is currently under investigation in a Phase 3 clinical program, investigating the efficacy and safety of Humira for the treatment of non-infectious uveitis.

RELATED: Ophthalmic Disorders Resource Center

Humira is a TNF blocker already approved to reduce the signs and symptoms of moderate-to-severe rheumatoid arthritis, moderate-to-severe polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, moderate-to-severe Crohn’s disease; to induce remission in moderate-to-severe ulcerative colitis; and to treat moderate-to-severe chronic plaque psoriasis.

For more information call (800) 633-9110 or visit